Integer stock trades steady as recent earnings and guidance frame investor expectations

Integer Holdings Corporation (ISIN US45826J1051) is a medical device outsource manufacturer whose Integer stock offers investors exposure to contract production of cardiac rhythm management, neuromodulation, vascular, and advanced surgical products. In its most recently reported quarter, Integer generated revenue in the mid-hundreds of millions of dollars, with year-over-year growth in the single- to low-double-digit range, according to public filings and investor communications. As of a recent trading day in 2026, the companys market capitalization stands in the low-single-digit billions of USD, reflecting how the equity market prices its role in supplying critical components to larger medical technology and healthcare firms.

Revenue up year over year

Integer Holdings Corporation reported quarterly revenue in its latest filing in the region of roughly $400 million, marking an increase compared with the same quarter a year earlier. The year-over-year comparison shows that revenue expanded by a high-single-digit to low-double-digit percentage, illustrating steady top-line growth despite a competitive landscape in contract manufacturing. This revenue base is diversified across end markets including cardiac rhythm management devices, neuromodulation leads and cables, vascular access products, and surgical instruments, which helps to stabilize demand across economic cycles.

The companys financial disclosures indicate that adjusted operating income and net income also improved versus the prior-year period, reflecting both scale effects and ongoing cost controls. The operating margin has been maintained in a mid-teens percentage range, with management signaling a focus on efficiency in manufacturing and supply-chain operations. Compared with earlier periods where margins were temporarily pressured by inflation and logistics constraints, the latest figures show a modest recovery, with basis-point improvements relative to the prior year.

On a trailing twelve-month basis, Integer has reported revenue exceeding $1 billion, underlining that the group has achieved a scale where contract manufacturing economics can support investments in automation and quality systems. This multi-quarter revenue trajectory shows a compounded growth rate in the mid-single-digit percentage range, with pockets of stronger expansion in specific product categories. Investors commonly compare this growth profile with larger diversified device makers, highlighting that Integer operates as a B2B supplier rather than as a branded end-product marketer, which influences both margin structure and valuation multiples.

Guidance, earnings, and margin mix

In its most recent guidance commentary, Integer management outlined expectations for continued revenue growth and margin progression over the current fiscal year, with the outlook framed in terms of mid-single- to high-single-digit percentage growth ranges. The guidance range contrasts with the prior year, when growth was temporarily skewed by pandemic-related recovery effects and supply-chain normalization. The current guidance therefore serves as a more normalized baseline, and the midpoint implies that the company expects to add tens of millions of dollars in additional annual revenue compared with the previous year.

Earnings per share (EPS) on a diluted basis in the latest reported quarter is in the range of roughly $0.60 to $1.00, based on public data for comparable periods and the companys own disclosures, with EPS up versus the prior-year quarter by a tangible margin. That EPS growth percentage, while varying depending on exact adjustments, shows that profitability is growing faster than revenue, a sign that fixed costs are being leveraged across a larger production volume. Investors often monitor this EPS progression relative to consensus expectations, and recent results have tended to be in line with, or modestly above, aggregated analyst estimates when normalized for one-off items.

Integer also reports adjusted EBITDA as a supplementary performance measure, providing visibility into cash-generative operations before non-cash charges. On a quarterly basis, adjusted EBITDA is typically around a quarter to a third of revenue, giving an implied adjusted EBITDA margin in the mid- to high-teens percentage range. Compared with the prior-year quarter, EBITDA margin has shown incremental improvement, supported by mix shifts towards higher-value components and services. This margin profile is an important reference point for investors in assessing whether Integer can maintain competitive pricing while absorbing labor and material cost changes.

The balance-sheet context helps explain the companys risk-return profile. Integer carries long-term debt in the hundreds of millions of dollars, stemming from historical acquisitions and capital investments. However, leverage ratios, such as net debt to adjusted EBITDA, are maintained in a range that is typical for established industrial and healthcare suppliers. Over recent periods, the company has directed cash flow towards both debt reduction and selective capital expenditure, for example in capacity expansions and equipment upgrades, which can support future revenue and margin growth.

Medical device components drive revenue

Integer generates most of its revenue by producing components and subassemblies that are used in implantable and external medical devices, particularly in cardiac rhythm management and neuromodulation. Customers typically include larger medical technology companies that rely on Integer for design support, precision manufacturing, and quality assurance. The cardiac rhythm management segment, encompassing leads, connectors, and related components used in pacemakers and implantable defibrillators, contributes a significant portion of revenue and tends to grow along with global procedure volumes.

Neuromodulation products, such as leads and extensions used with implantable neurostimulators, represent another important revenue stream. Over recent years, neuromodulation has grown at a faster pace than some legacy device areas, driven by expanding indications and innovations in chronic pain and movement-disorder therapies. Integer, as a supplier, benefits from this trend, with neuromodulation-related sales increasing from a lower base and contributing to overall top-line growth. In publicly discussed segment information, neuromodulation revenue has posted double-digit percentage growth in specific years, outpacing the companywide average.

The company also manufactures vascular and vascular access products, including catheters, sheaths, and other access tools used by interventional cardiologists and radiologists. This portfolio broadens the customer base and adds recurring revenue tied to procedural volumes rather than implant counts alone. Advanced surgical tools and orthopedic components further diversify the mix, providing exposure to surgical procedure growth and hospital capital-spending cycles.

Integer complements manufacturing with engineering and design services, which can embed the company more deeply in customer programs. These services, while a smaller portion of revenue relative to volume manufacturing, can command higher margins and create long-term design-in relationships. For investors, the combination of contract manufacturing scale with specialized engineering support underpins the companys ability to win and retain multi-year supply agreements, which in turn provide visibility into future revenue streams.

Integer stock valuation and trading context

Integer stock is listed on a major US exchange and trades in USD, with recent share prices in the tens of dollars per share and a market capitalization in the low-single-digit billions of USD. The shares tend to trade with modest daily volume, reflecting the companys role as a mid-cap industrial and healthcare supplier rather than a large-cap branded device maker. Over the past twelve months, the stock price has moved within a range where the difference between the 52-week high and 52-week low spans several tens of percent, capturing both broader market volatility and company-specific news.

Investors often benchmark Integer stock against broader indices such as the S&P 500 or healthcare subsector indices, although the company is not among the largest constituents of those benchmarks. Relative performance over one-year and multi-year periods has at times reflected how the market values contract manufacturing exposure versus pure-play device exposure. In periods where outsourcing trends and supply-chain consolidation are prominent themes, Integer shares can attract attention as a way to gain exposure to those structural shifts.

Valuation metrics such as the ratio of enterprise value to EBITDA (EV/EBITDA) and price-to-earnings (P/E) are commonly used to compare Integer with peers in the contract manufacturing and medical technology sectors. Publicly available data places the companys EV/EBITDA multiple in a mid-teens range and its P/E multiple likewise in a mid-teens to low-twenties range, depending on whether trailing or forward metrics are used. These multiples are influenced by the companys leverage level, growth trajectory, and margin profile. Compared with larger diversified device companies that may trade at higher P/E ratios, Integer often reflects both its supplier status and its smaller scale.

Dividend policy also influences investor perception. Integer has historically prioritized reinvestment in capacity and technology over paying a large dividend, although any existing dividend yield tends to be modest compared with high-yield industrials or utilities. For some shareholders, this reinvestment focus aligns with a growth and innovation thesis, while others prefer more income-oriented stocks. Analysts and investors therefore often view Integer through a total-return lens that combines potential capital appreciation from earnings growth with any income component.

Product and manufacturing capabilities

Among its representative offerings, Integer is well known in the industry for high-reliability leads and cables used in cardiac rhythm management devices. These components must meet stringent durability and biocompatibility standards, as failures can have direct consequences for patient safety. As a result, customer device makers rely on Integer not only for manufacturing capacity but also for robust quality systems and process validation.

Beyond cardiac products, Integer invests in capabilities such as precision machining, laser processing, forming, and assembly techniques that can be applied across various device categories. This manufacturing toolkit allows the company to support new product introductions and design changes without requiring customers to bring all production in-house. In segments such as neuromodulation, Integer may help customers translate novel electrode configurations or lead designs into manufacturable products, bridging the gap between R&D and commercial supply.

To maintain competitiveness, Integer deploys capital towards automation, inspection technology, and digital manufacturing systems. These investments can improve yield, reduce labor costs, and enhance traceability, all of which are important in regulated medical-device supply chains. While such capital spending temporarily increases expenses, over time it can support higher margins and greater throughput, contributing to the operating metrics noted in recent quarters.

Integer stock and recent pricing

Integer stock, quoted in USD on its primary US exchange, recently traded at a share price in the range of approximately $70 to $100, situating the company firmly within the mid-cap bracket. The as-of date for this general price band is in 2026, and the implied equity valuation corresponds to a market capitalization in the low-single-digit billions of USD. This price range positions the shares near the mid-point of their twelve-month historical band, neither at a fresh high nor at a recent low, suggesting that investors are currently balancing revenue growth and margin improvement against sector and macroeconomic risks.